Inventor · disambiguated record
Sharon M. Laughlin
Also filed as: LAUGHLIN SHARON · LAUGHLIN SHARON M
6 granted patents·6 pending applications·52 citations·filing 1995–2017
80Inventor score
Files withSANOFI WINTHROP INC3SUNOVION PHARMACEUTICALS INC3SEPRACOR INC2LAUGHLIN SHARON M1SANOFI SA1
Top patents by PatentIndex Score
12 records- 0167US6197787B1Pharmaceutical formulations containing poorly soluble drug substancesSANOFI SYNTHELABO·Filed 1999·Granted Mar 6, 2001·34 cites·50 claims
- 0259US8957114B2Formulations, salts and polymorphs of transnorsertraline and uses thereofLAUGHLIN SHARON M·Filed 2010·Granted Feb 17, 2015·1 cites·8 claims
- 0355US2006035940A1(S)-Amlodipine malateSEPRACOR INC·Filed 2005·Application pending·0 cites
- 0452US2009005457A1Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereofSIZENSKY MICHAEL·Filed 2008·Application pending·0 cites
- 0547US2018071230A1Formulations, salts and polymorphs of transnorsertraline and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0646US2006030602A1(S)-amlodipine malateSEPRACOR INC·Filed 2005·Application pending·0 cites
- 0744US5837714ASolid pharmaceutical dispersionsSANOFI SA·Filed 1997·Granted Nov 17, 1998·9 cites·7 claims
- 0841US2016355457A1Solid Forms Comprising(-)-O-Desmethylvenlafaxine And Uses ThereofSUNOVION PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0940US2015196502A1Formulations, salts and polymorphs of transnorsertraline and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1036US5776987APharmaceutical suspension formulationSANOFI WINTHROP INC·Filed 1997·Granted Jul 7, 1998·4 cites·4 claims
- 1135US5656288AStable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositionsSANOFI WINTHROP INC·Filed 1995·Granted Aug 12, 1997·2 cites·11 claims
- 1232US5760056APharmaceutical formulationSANOFI WINTHROP INC·Filed 1997·Granted Jun 2, 1998·2 cites·3 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →